<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149941</url>
  </required_header>
  <id_info>
    <org_study_id>02279</org_study_id>
    <nct_id>NCT01149941</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Ibuprofen 200 mg Gel Capsules of Dr. Reddy's Laboratories Under Fasting Condition</brief_title>
  <official_title>Randomized, 2-way Crossover, Bioequivalence Study of Ibuprofen 200 mg Gel Capsules and Advil Liquigels 200 mg Gel Capsules Administered as 1 x 200 mg Gel Capsules in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the rate and extent of absorption of ibuprofen 200 mg
      gelcaps (test) versus Advil liquigels (reference) administered as 1 x 200 mg gelcap under
      fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, 2-way crossover, bioequivalence study of Ibuprofen 200 mg gel capsules and Advil
      liquigels 200 mg gel caps administered as 1 x 200 mg gel capsule in healthy subjects under
      fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">November 2002</completion_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibuprofen 200 mg gel Capsules of Dr. Reddy's laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Advil liquigels 200 mg gel capsules of Wyeth Consumer Healthcare</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited</description>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_label>Advil</arm_group_label>
    <other_name>Advil liquigels 200 mg gel capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects will be females and/or males, smokers and/or non-smokers, 18 years of age and
        older.

        Exclusion Criteria:

          -  Clinically significant illnesses within 4 weeks of the administration of study
             medication.

          -  Clinically significant surgery within 4 weeks prior to the administration of the study
             medication.

          -  Any clinically significant abnormality found during medical screening.

          -  Any reason which, in the opinion of the medical subinvestigator, would prevent the
             subject from participating in the study.

          -  Abnormal laboratory tests judged clinically significant.

          -  Positive urine drug screen at screening.

          -  Positive testing for hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) at
             screening.

          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood
             pressure lower than 90 or over 140 mmHg, or diastolic blood pressure lower than 50 or
             over 90 mmHg; or heart rate less than 50 or over 100 bpm) at screening.

          -  Subjects with Body Mass Index (BMI) â‰¥30.0.

          -  History of significant alcohol abuse within six months of the screening visit or any
             indication of the regular use of more than fourteen units of alcohol per week (1 unit
             = 150 mL of wine or 360 mL of beer or 45 mL of alcohol 40%).

          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana)
             within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine
             (PCP) and crack) within 1 year of the screening visit.

          -  History of allergic reactions to ibuprofen or other nonsteroidal anti- inflammatory
             drug NSAIDs (e.g. aspirin, diclofenac,diflunisal, etodolac, ketoprofen, fenoprofen,
             floctafenine, flurbiprofen, indomethacin,ketorolac, mefenamic acid, nabumetone,
             naproxen, oxaprozin, piroxicam, salsalate, sulindac, tenoxicam, tiaprofenic acid and
             tolmetin).

          -  History of allergic reactions to heparin.

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids,
             rifampin/rifabutin;examples of inhibitors: antidepressants, cimetidine, diltiazem,
             erythromycin,ketoconazole, Mono Amine Oxidase (MAO) inhibitors, neuroleptics,
             verapamil, quinidine) within 30 days prior to administration of the study medication.

          -  Use of an investigational drug or participation in an investigational study within 30
             days prior to administration of the study medication.

          -  History or presence of any clinically significant gastrointestinal pathology (e.g.
             chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms
             (e.g. diarrhea, vomiting), liver or kidney disease or other conditions known to
             interfere with the absorption, distribution, metabolism or excretion of the drug.

          -  Any history or presence of clinically significant neurological, endocrinal,
             cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease.

          -  Use of prescription medication within 14 days prior to administration of study
             medication or over-the-counter products (including natural food supplements, vitamins,
             garlic as supplement) within 7 days prior to administration of study medication,
             except for topical products without systemic absorption.

          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the
             medical subinvestigator, contraindicates the subject's participation in this study.

          -  Subjects who have had a depot injection or an implant of any drug 3 months prior to
             administration of study medication.

          -  Donation of plasma (500 mL) within 7 days. Donation or loss of whole blood prior to
             administration of the study medication as follows:

               -  less than 300 mL of whole blood within 30 days or

               -  300 mL to 500 mL of whole blood within 45 days or

               -  more than 500 mL of whole blood within 56 days

          -  Subjects who have consumed food or beverages containing grapefruit (e.g. fresh,
             canned,or frozen) within 7 days prior to administration of the study medication.

          -  Subjects with history or known presence of active peptic ulcer or heartburn.

          -  Subjects with history or known presence of gastrointestinal bleeding.

          -  Subjects with history or known presence of bronchospastic reactivity (e.g. asthma).

        For females:

          -  Breast-feeding subjects.

          -  Positive urine pregnancy test at screening (performed on all females).

          -  Female subjects of childbearing potential who have had unprotected sexual intercourse
             with any non-sterile male partner (i.e. male who has not been sterilized by vasectomy
             for at least 6 months) within 14 days prior to study drug administration. The
             acceptable methods of contraception are:

               -  Condom + spermicide

               -  Diaphragm + spermicide

               -  Intrauterine contraceptive device (placed at least 4 weeks prior to study drug
                  administration).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Girard, MD</last_name>
    <role>Study Director</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaphann Inc.</name>
      <address>
        <city>Quebec</city>
        <zip>GIV 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2010</study_first_submitted>
  <study_first_submitted_qc>June 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2010</study_first_posted>
  <last_update_submitted>June 25, 2010</last_update_submitted>
  <last_update_submitted_qc>June 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Rama Krishna Bangaru / Assistant Manager</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Crossover</keyword>
  <keyword>Ibuprofen</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

